Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy

Journal of Clinical Endocrinology and Metabolism

Volumn 86, Issue 2, 2001, Pages 504-510

  Rietschel, Petra ^a   Hadigan, Colleen ^a   Corcoran, Colleen ^a   Stanley, Takara ^a   Neubauer, Gregory ^a   Gertner, Joseph ^b   Grinspoon, Steven ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b EMD SERONO INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE;

ABDOMINAL PAIN; ADULT; ARTICLE; BODY FAT; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; MALE; NUTRITIONAL STATUS; PRIORITY JOURNAL; VISCERA;

ABDOMEN; ADIPOSE TISSUE; ADULT; BLOOD GLUCOSE; BODY COMPOSITION; BODY CONSTITUTION; BODY MASS INDEX; HIV INFECTIONS; HUMAN GROWTH HORMONE; HUMANS; HYDROCORTISONE; INSULIN-LIKE GROWTH FACTOR I; LIPIDS; LIPODYSTROPHY; LIPOPROTEINS; MALE; MIDDLE AGED; REFERENCE VALUES; SKIN; VISCERA;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0035090230     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.86.2.504     Document Type: Article

References (30)

1. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving protease inhibitor therapy
2. Lipodystrophy associated with an HIV-protease inhibitor
3. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor associated lipodystrophy, hyperlipidemia, and diabetes mellitus: A cohort study
4. Visceral abdominal-fat accumulation associated with use of indinavir
5. Diabetes, insulin resistance and dyslipidemia in lipodystrophic HIV-infected patient on highly active antiretroviral therapy (HAART)
6. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection
7. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome
8. Differential impact of age, sex steroid hormones, and obesity on basal versus pulsatile growth hormone secretion in men as assessed in an ultrasensitive chemiluminescence assay
9. Dual defects in pulsatile growth hormone secretion and clearance subserve the hyposomatotropism of obesity in man
10. Arginine potentiates but does not restore the blunted growth hormone response to growth-hormone releasing hormone in obesity
11. Assessment of growth hormone (GH) secretion in men with adult-onset GH deficiency compared with that in normal men - A clinical research center study
12. Height and weight tables
13. Dual-energy x-ray absorptiometry for total-body and regional bone-mineral and soft-tissue composition
14. Assessment of abdominal fat content by computed tomography
15. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Normal reference laboratory values
16. Serum markers of metabolic dysregulation in HIV disease
17. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors
18. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1 infected patients
19. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy
20. Loss of lean body mass and muscle mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome and wasting
21. Circadian growth hormone secretion in asymptomatic human immune deficiency virus infection and acquired immunodeficiency syndrome
22. Serum growth hormone responses to growth-hormone releasing hormone in non-obese and obese adults with hypopituitarism
23. Low concentrations of insulin-like growth factor-I in abdominal obesity
24. The distal axis of growth hormone (GH) in nutritional disorders: GH-binding protein, insulin-like growth factor-I (IGF-I), and IGF-I receptors in obesity and anorexia nervosa
25. Effect of central cholinergic neurotransmission enhancement by pyridostigmine on the growth hormone secretion elicited by clonidine, arginine, or hypoglycemia in normal and obese subjects
26. Cholinergic receptor activation by pyridostigmine restores growth hormone (GH) responsiveness to GH-releasing hormone administration in obese subjects: Evidence for hypothalamic somatostatinergic participation in the blunted GH release of obesity
27. Effect of cholinergic enhancement by pyridostigmine on growth hormone secretion in obese adults and children
28. In vitro and in vivo growth hormone responsiveness to growth hormone-releasing factor in male and female Zucker rats
29. Mechanisms of impaired growth hormone secretion in genetically obese Zucker rats; roles of growth hormone-releasing factor and somatostatin
30. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism and reduces diastolic blood pressure